Division of Mitsubishi Chemical Holdings Corp.
Latest From Medicago Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Japanese mid-sized firm Mitsubishi Tanabe Pharma is building up its independent US commercial operations with a view to conducting the in-house marketing of new products, starting with an ALS therapy.
While the initial US response to the current Ebola crisis got off to a bumpy start, the fact there are two vaccines in efficacy trials in West Africa and several drugs in development against the deadly disease is proof the medical countermeasure (MCM) system is working, top officials insisted during testimony at a 26 February Capitol Hill hearing.
The Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services, has awarded contracts to biotech Medicago and nonprofit research and development firm Fraunhofer to make ZMapp-like Ebola drugs, the head of the agency revealed on 24 February.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Large Molecule
- Synthesis Technologies, Production Processes
- Drug Discovery Tools
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Mitsubishi Chemical Holdings Corp.
- Senior Management
Andy Sheldon, Pres. & CEO
Pierre Labbé, VP, CFO
Louis-Philippe Vézina, PhD, CSO
Frederic Ors, VP, Bus. Dev.
- Contact Info
Phone: (418) 658-9393
1020, route de l'Église, Bureau 600
Montreal, G1V 3V9
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.